A US-based large pharmaceutical firm forms partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The firm looks globally for opportunities.
The firm focuses on therapeutic assets in oncology (including immuno-oncology), immunology, and neurodegenerative diseases. The firm is also interested in fibrotic diseases of the liver (such as HBV). The firm is open to biologic, small molecule and cell therapy opportunities. The firm will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com